Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597388 · ClinicalTrials.gov registry record · Phase 1
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT01597388: Completed Phase 1 study, sponsored by AstraZeneca.
NCT01597388 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 99 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01597388, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Interventions
- DRUG Fulvestrant
- DRUG AZD2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2012-05-08 |
| Est. Completion | 2026-01-13 |
| Phase | Phase 1 |
What the finished NCT01597388 record still lists
NCT01597388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT01597388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01597388 about?
NCT01597388 is a clinical study titled "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer". The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
What is the current status of trial NCT01597388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2012-05-08. Estimated completion is 2026-01-13.
What interventions are being tested in trial NCT01597388?
The interventions under investigation include: Fulvestrant (DRUG), AZD2014 (DRUG).
Who is sponsoring clinical trial NCT01597388?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01597388's enrollment target sits among peer trials
99 590th of 2000 higher than 1,409 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI